<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03905811</url>
  </required_header>
  <id_info>
    <org_study_id>201902772</org_study_id>
    <nct_id>NCT03905811</nct_id>
  </id_info>
  <brief_title>Terazosin for Parkinson's Disease</brief_title>
  <acronym>TZ-PD</acronym>
  <official_title>A Pilot Study of Terazosin for Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jordan Schultz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The TZ-PD trial will be a 1:1 (active:placebo) randomized, double-blind, placebo-controlled&#xD;
      Phase II trial to evaluate the safety and tolerability of terazosin for the treatment of PD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a single center, randomized, double-blind, controlled, pilot study to assess the&#xD;
      safety and tolerability of terazosin (TZ) at a dose of 5 milligrams (MG) daily for patients&#xD;
      with PD. The primary goal of this study is to assess the safety and tolerability of TZ in&#xD;
      patients with PD. This is a pilot study and is not powered to assess efficacy of this&#xD;
      medication. Our hope is that this study will guide future studies of this (and similar)&#xD;
      medications for the disease modification of PD. This study is also aimed to learn more about&#xD;
      how patients with produce and use energy and if TZ can help to reverse energy deficits that&#xD;
      appear in PD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2019</start_date>
  <completion_date type="Actual">November 18, 2020</completion_date>
  <primary_completion_date type="Actual">June 5, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Intervention-related Adverse Events Between Treatment Arms</measure>
    <time_frame>12 weeks</time_frame>
    <description>All patient-reported adverse events will be determine to be related to the study intervention by the site investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Falls Between Treatment Arms</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of participants in each group who report a fall, as determined by the site investigator, will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Drop-out From Study/Discontinuation of Study Intervention for Any Reason</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of participants in each group who drop out of the study for any reason will be compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Assess the Mean Change in Systolic and Diastolic Blood Pressures</measure>
    <time_frame>At 2 weeks, 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Systolic and Diastolic Blood Pressure</measure>
    <time_frame>From baseline to 2 weeks to 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Falls Between Placebo and Active Group</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Intolerable Side Effects Between Placebo and Active Group</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Study Discontinuation Between Placebo and Active Group</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Overall Compliance Between Placebo and Active Group as Assessed by Pill Counts</measure>
    <time_frame>At 2 weeks, 6 weeks and 12 weeks</time_frame>
    <description>All participants will be asked to bring their study intervention bottles to their 6 week visit and their 12 week visit so the Investigational Drug Pharmacy can count remaining pills and assess compliance based on dispensing history.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Terazosin administered 5 mg once daily p.o. for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered once daily p.o. for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terazosin 5 MG</intervention_name>
    <description>5 milligrams by mouth daily at bedtime</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>Hytrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>1 capsule by mouth daily at bedtime</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women aged 40 and older with the diagnosis of idiopathic PD per UK Brain Bank&#xD;
             criteria&#xD;
&#xD;
          -  Hoehn-Yahr Stage I-III, on stable dopaminergic treatment regimen for â‰¥4 weeks prior to&#xD;
             baseline.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects unwilling or unable to give informed consent&#xD;
&#xD;
          -  Secondary parkinsonism (e.g., drug induced)&#xD;
&#xD;
          -  Parkinson-plus syndromes&#xD;
&#xD;
          -  History of brain surgery for PD such as deep brain stimulation&#xD;
&#xD;
          -  No confounding acute or unstable medical, psychiatric, orthopedic condition. Subjects&#xD;
             who have hypertension, diabetes mellitus, depression, or other common age-related&#xD;
             illness will be included if their disease under control with stable treatment regimen&#xD;
             for at least 30 days.&#xD;
&#xD;
          -  Neurogenic orthostatic hypotension defined as symptomatic decrease in BP &gt; 20mmHg&#xD;
             systolic or &gt; 10mmHg diastolic and HR increase &lt; 20bpm on supine to sitting or&#xD;
             standing.&#xD;
&#xD;
          -  Clinically significant traumatic brain injury or post-traumatic stress disorder&#xD;
&#xD;
          -  Presence of other known medical or psychiatric comorbidity that in the investigator's&#xD;
             opinion would compromise participation in the study&#xD;
&#xD;
          -  Presence of dementia per Movement Disorder Society Level I criteria&#xD;
&#xD;
          -  Major depression, bipolar affective disorder, or other mental health disorders that&#xD;
             are sufficiently severe to increase adverse event risk or impact neuropathy assessment&#xD;
             in the opinion of the responsible site principal investigator.&#xD;
&#xD;
          -  Subjects with clinically significant depression as determined by a Beck Depression&#xD;
             Inventory score greater than 21 at the screening visit&#xD;
&#xD;
          -  Current suicidal ideation within one year prior to the baseline visit as evidenced by&#xD;
             answering &quot;yes&quot; to Questions 4 or 5 on the suicidal ideation portion of the&#xD;
             Columbia-Suicide Severity Rating Scale (C-SSRS)&#xD;
&#xD;
          -  If the participant has a Beck Anxiety Score greater than 22 at the initial screening&#xD;
             visit.&#xD;
&#xD;
          -  History of exposure to typical or atypical antipsychotics or other dopamine blocking&#xD;
             agents within 6 months prior to the baseline visit&#xD;
&#xD;
          -  Use of investigational drugs within 30 days before screening&#xD;
&#xD;
          -  Subjects have to be on a stable regimen of central nervous system acting medications&#xD;
             (benzodiazepines, antidepressants, hypnotics) for 30 days prior to the baseline visit&#xD;
&#xD;
          -  Use of doxazosin, alfuzosin, prazosin, or tamsulosin&#xD;
&#xD;
          -  For female participant, pregnancy, or plans for child-bearing during study period&#xD;
&#xD;
          -  Participant is restricted from traveling to and from the study site&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordan Schultz, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nandakumar Narayanan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 1, 2019</study_first_submitted>
  <study_first_submitted_qc>April 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <results_first_submitted>July 9, 2021</results_first_submitted>
  <results_first_submitted_qc>July 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 2, 2021</results_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Jordan Schultz</investigator_full_name>
    <investigator_title>PharmD</investigator_title>
  </responsible_party>
  <keyword>terazosin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terazosin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Upon reasonable request with justification for request from qualified researchers, anonymized data will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>One year after completion of this study</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may contact the PI of this study with reasonable requests for data to be shared. Inquiries must include what hypothesis the researcher intends to test using the shared data.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT03905811/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active</title>
          <description>Terazosin administered 5 mg once daily p.o. for 12 weeks&#xD;
Terazosin 5 MG: 5 milligrams by mouth daily at bedtime</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo administered once daily p.o. for 12 weeks&#xD;
Placebo oral capsule: 1 capsule by mouth daily at bedtime</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active</title>
          <description>Terazosin administered 5 mg once daily p.o. for 12 weeks&#xD;
Terazosin 5 MG: 5 milligrams by mouth daily at bedtime</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo administered once daily p.o. for 12 weeks&#xD;
Placebo oral capsule: 1 capsule by mouth daily at bedtime</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.8" spread="6.1"/>
                    <measurement group_id="B2" value="68.8" spread="6.6"/>
                    <measurement group_id="B3" value="66.4" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Intervention-related Adverse Events Between Treatment Arms</title>
        <description>All patient-reported adverse events will be determine to be related to the study intervention by the site investigator.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Terazosin administered 5 mg once daily p.o. for 12 weeks&#xD;
Terazosin 5 MG: 5 milligrams by mouth daily at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered once daily p.o. for 12 weeks&#xD;
Placebo oral capsule: 1 capsule by mouth daily at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Intervention-related Adverse Events Between Treatment Arms</title>
          <description>All patient-reported adverse events will be determine to be related to the study intervention by the site investigator.</description>
          <units>Event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Falls Between Treatment Arms</title>
        <description>The number of participants in each group who report a fall, as determined by the site investigator, will be reported.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Terazosin administered 5 mg once daily p.o. for 12 weeks&#xD;
Terazosin 5 MG: 5 milligrams by mouth daily at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered once daily p.o. for 12 weeks&#xD;
Placebo oral capsule: 1 capsule by mouth daily at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Falls Between Treatment Arms</title>
          <description>The number of participants in each group who report a fall, as determined by the site investigator, will be reported.</description>
          <units>Event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Drop-out From Study/Discontinuation of Study Intervention for Any Reason</title>
        <description>The number of participants in each group who drop out of the study for any reason will be compared.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Terazosin administered 5 mg once daily p.o. for 12 weeks&#xD;
Terazosin 5 MG: 5 milligrams by mouth daily at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered once daily p.o. for 12 weeks&#xD;
Placebo oral capsule: 1 capsule by mouth daily at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Drop-out From Study/Discontinuation of Study Intervention for Any Reason</title>
          <description>The number of participants in each group who drop out of the study for any reason will be compared.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Mean Change in Systolic and Diastolic Blood Pressures</title>
        <time_frame>At 2 weeks, 6 weeks and 12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Systolic and Diastolic Blood Pressure</title>
        <time_frame>From baseline to 2 weeks to 6 weeks and 12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Falls Between Placebo and Active Group</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Intolerable Side Effects Between Placebo and Active Group</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Study Discontinuation Between Placebo and Active Group</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences in Overall Compliance Between Placebo and Active Group as Assessed by Pill Counts</title>
        <description>All participants will be asked to bring their study intervention bottles to their 6 week visit and their 12 week visit so the Investigational Drug Pharmacy can count remaining pills and assess compliance based on dispensing history.</description>
        <time_frame>At 2 weeks, 6 weeks and 12 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 week</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active</title>
          <description>Terazosin administered 5 mg once daily p.o. for 12 weeks&#xD;
Terazosin 5 MG: 5 milligrams by mouth daily at bedtime</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo administered once daily p.o. for 12 weeks&#xD;
Placebo oral capsule: 1 capsule by mouth daily at bedtime</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizzy/Lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Unsteady</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jordan Schultz</name_or_title>
      <organization>University of Iowa</organization>
      <phone>3193849388</phone>
      <email>jordan-schultz@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

